Is ACE-031 FDA approved?

ACE-031 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is CJC-1295 DAC FDA approved?

CJC-1295 DAC is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ACE-031 administered in research settings?

In research settings, ACE-031 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is CJC-1295 DAC administered in research settings?

In research settings, CJC-1295 DAC is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ACE-031 vs CJC-1295 DAC

Peptide Comparison

ACE-031 vs CJC-1295 DAC

Name: ACE-031 vs CJC-1295 DAC — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

ACE-031

ACVR2B-Fc

PerformanceInvestigationalResearch Only

Half-life: ~14 days

4 providers listed

Full ACE-031 profile →

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

1 providers listed

Full CJC-1295 DAC profile →

Bottom line

ACE-031 and CJC-1295 DAC target different goals — ACE-031 for myostatin/activin inhibition, CJC-1295 DAC for GH and IGF-1 elevation studied in a single-dose human PK trial. They're compared here for reference, not as direct substitutes.

Quick Verdict

ACE-031

Half-life

~14 days

CJC-1295 DAC

Half-life

6–8 days

Different Goals

ACE-031 and CJC-1295 DAC target different goals — ACE-031 for Muscle & Myostatin, CJC-1295 DAC for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

ACE-031

CJC-1295 DAC

Mechanism Family

Muscle & Myostatin

GH / IGF Axis

Half-life

~14 days

6–8 days

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Providers

4 listed

1 listed

Avail. Notes

Activin receptor IIB-Fc fusion (ACVR2B decoy) by Acceleron Pharma. Phase 2 for Duchenne MD halted 2013 due to AEs (epistaxis, telangiectasia). Development discontinued. Previously held IND.

Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.

Research Evidence

ACE-031

RCT · 1 key study · most recent 2017

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

Research Citations

ACE-031

RCT2017 · Muscle & Nerve

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a rando…

CJC-1295 DAC

RCT2006 · Journal of Clinical Endocrinology and Metabolism

Effects of a single injection of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy…

About ACE-031

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

Research Areas

myostatin/activin inhibitionmuscle mass increasebone density improvement

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas

GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ACE-031

Reported (Unverified — Pending Clinical Review)

cardiovascular diseasetelangiectasia riskbleeding disorderspregnancy

No established clinical contraindications

CJC-1295 DAC

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Price (per mg)

ACE-031

$119.00/mg

$78.70 – $161.50 range

8 vendors

View price index →Find providers →

CJC-1295 DAC

$10.63/mg

$9.74 – $15.25 range

20 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ACE-031

4 listed

Browse directory →

Providers offering

CJC-1295 DAC

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ACE-031 vs CJC-1295 DAC — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ace-031/cjc-1295-dac

https://peptidebase.io/peptides/compare/ace-031/cjc-1295-dac Methodology License Download JSON Download CSV